Clinical Trial Update: Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating MK-3475 (pembrolizumab) in combination with stereotactic body radiotherapy in patients with metastatic melanoma or lung cancer has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Melanoma

Drugs mentioned

• MK-3475 (pembrolizumab)

Snippet

Sponsor: Yale University | Conditions: Melanoma, Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-10-31